000			03556nam a22003855i 4500
001			82205
003			ES-MaUEC
005			20230207040401.0
007			cr nn 008mamaa
008			141110s2015 gw | s |||| 0|eng d
020			_a9783319105277
024	7		_a10.1007/978-3-319-10527-7 _2doi
050		4	_aRC159.A5 _b2015 EB
100	1		_aKiang, Tony K. L. _0Local _994973
245	1	0	_aClinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials _cby Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
260			_aCham _bSpringer International Publishing _bImprint: Adis _c2015.
300			_a1 recurso en línea (VII, 146 páginas) _b1 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aIntroduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
520	3		_aThis comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested.Â{u026E} addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.Â{uE000}
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		0	_9156795 _aPromoción de la salud
650		7	_aEnfermedades tropicales _2embne _9140433
650		7	_aFarmacia _2embne _9137891
700	1		_aWilby, Kyle John _0Local _994974
700	1		_aEnsom, Mary H. H. _0Local _994975
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-10527-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12908459 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC159.A5 K536 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11576133 _z06-04-17
999			_c82205 _d82205 _x1